MediWound (MDWD) director details options, RSU and share holdings

Rhea-AI Filing Summary

MediWound Ltd. director Vickie Rae Driver filed an initial ownership report detailing her equity interests in the company. She directly holds ordinary shares, including shares underlying restricted stock units granted on March 4, 2026 that vest in full one year after the grant date.

She also holds several stock option awards to buy ordinary shares at exercise prices ranging from 11.8850 to 37.5200 per share, with expiration dates between 2030 and 2036. This filing records existing holdings and does not show any new purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Driver Vickie Rae

(Last) (First) (Middle)

C/O MEDIWOUND LTD.

42 HAYARKON STREET

(Street)

YAVNE 8122745

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MediWound Ltd. [ MDWD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	1,910	D
Ordinary shares(1)	750	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	06/29/2021	06/29/2030	Ordinary shares	14,285	$12.25	D
Stock Option (right to buy ordinary shares)	06/15/2022	06/15/2031	Ordinary shares	1,607	$37.52	D
Stock Option (right to buy ordinary shares)	05/16/2023	05/16/2032	Ordinary shares	5,357	$14.42	D
Stock Option (right to buy ordinary shares)	05/31/2024	05/30/2033	Ordinary shares	5,900	$11.885	D
Stock Option (right to buy ordinary shares)	02/26/2025	02/26/2034	Ordinary shares	7,542	$12.729	D
Stock Option (right to buy ordinary shares)	02/11/2026	02/11/2035	Ordinary shares	5,600	$18.54	D
Stock Option (right to buy ordinary shares)	(2)	03/04/2036	Ordinary shares	6,250	$17.6	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

2. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

	/s/ Yaron Meyer, attorney-in-fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Vickie Rae Driver report holding in MediWound (MDWD) on this Form 3?

She reports direct ownership of ordinary shares and multiple stock options to buy additional ordinary shares at preset exercise prices, with expirations from 2030 to 2036, plus restricted stock units granted March 4, 2026 that vest fully after one year.

Are there any MediWound (MDWD) share purchases or sales reported in this Form 3?

No share purchases or sales are reported. The entries are classified as holdings, with transaction counts showing no buys, sells, exercises, gifts, or tax withholdings, indicating this filing simply records Vickie Rae Driver’s existing MediWound equity positions.

What stock option grants for MediWound (MDWD) does Vickie Rae Driver hold?

She holds several stock option awards to buy MediWound ordinary shares, with exercise prices such as $12.2500, $14.4200, $18.5400, and $17.6000 per share, and option expiration dates ranging from June 29, 2030 through March 4, 2036.

What are the terms of the MediWound (MDWD) RSUs granted to Vickie Rae Driver?

The ordinary shares in one row represent shares underlying RSUs granted on March 4, 2026. According to the footnote, these restricted stock units vest 100% on the one-year anniversary of the grant date, providing a single cliff vesting event.

How is Vickie Rae Driver’s ownership in MediWound (MDWD) classified in this filing?

All positions are reported as direct ownership. The records list ordinary shares, RSU-based shares, and stock options with the ownership code marked as direct and the direct_or_indirect field set to D, without any indirect entities or shared voting authority noted.

Does this MediWound (MDWD) Form 3 show remaining derivative positions for Vickie Rae Driver?

Yes. The derivative summary lists several unexercised stock options on ordinary shares, each with a specified exercise price and expiration date through 2036, indicating ongoing derivative exposure rather than completed option exercises or conversions.